In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
Editing can help build stronger muscles: Much of the controversy surrounding the gene-editing technology called CRISPR/Cas9 centers on the ethics of germline editing of human embryos to correct disease-causing mutations. For certain disorders such as muscular dystrophy, it may be possible to achieve therapeutic benefit by editing the faulty gene in somatic cells. In proof-of-concept studies, Long et al. , Nelson et al. , and Tabebordbar et al. used adeno-associated virus-9 to deliver the CRISPR/Cas9 gene-editing system to young mice with a mutation in the gene coding for dystrophin, a muscle protein deficient in patients with Duchenne muscular dystrophy. Gene editing partially restored dystrophin protein expression in skeletal and cardiac muscle and improved skeletal muscle function. Science , this issue p. 400 , p. 403 , p. 407
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Smaller genome editing proteins, such as the S. aureus Cas9, C. jejuni Cas9 and newly identified CRISPR-Cas enzymes, may circumvent this issue 23,61-65 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [62]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Two similar studies have described using the CRISPR/Cas9 system in vivo to increase expression of the dystrophin gene and improve muscle function in mouse models of DMD. 6 7”
From What is CRISPR/Cas9? (2016) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationRNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Self-citationBae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
RNA-programmed genome editing in human cells
Jinek, M., East, A., Cheng, A., Lin, S., Ma, E., & Doudna, J. (2013) · eLife · doi:10.7554/elife.00471 · Cited by 2,098
CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
Platt, R. J., Chen, S., Zhou, Y., Yim, M. J., Swiech, L., Kempton, H. R., Dahlman, J. E., Parnas, O., Eisenhaure, T. M., Jovanovic, M., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.014 · Cited by 2,001
Self-citationTargeted genome engineering in human cells with the Cas9 RNA-guided endonuclease
Cho, S. W., Kim, S., Kim, J. M., & Kim, J.-S. (2013) · Nature Biotechnology · doi:10.1038/nbt.2507 · Cited by 1,863
Mali, P., Aach, J., Stranges, P. B., Esvelt, K. M., Moosburner, M., Kosuri, S., Yang, L., & Church, G. M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2675 · Cited by 1,752
Therapeutic genome editing: prospects and challenges
Cox, D. B. T., Platt, R. J., & Zhang, F. (2015) · Nature Medicine · doi:10.1038/nm.3793 · Cited by 1,336
Self-citationThe Molecular Basis of Muscular Dystrophy in the mdx Mouse: a Point Mutation
Sicinski, P., Geng, Y., Ryder-Cook, A. S., Barnard, E. A., Darlison, M. G., & Barnard, P. J. (1989) · Science · doi:10.1126/science.2662404 · Cited by 1,276
In vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046
Self-citationImmune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
Long, C., Amoasii, L., Mireault, A. A., McAnally, J. R., Li, H., Sanchez-Ortiz, E., Bhattacharyya, S., Shelton, J. M., Bassel-Duby, R., & Olson, E. N. (2016) · Science · doi:10.1126/science.aad5725 · Cited by 937
Cirak, S., Arechavala-Gomeza, V., Guglieri, M., Feng, L., Torelli, S., Anthony, K., Abbs, S., Garralda, M. E., Bourke, J., Wells, D. J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60756-3 · Cited by 878
In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9
Swiech, L., Heidenreich, M., Banerjee, A., Habib, N., Li, Y., Trombetta, J., Sur, M., & Zhang, F. (2015) · Nature Biotechnology · doi:10.1038/nbt.3055 · Cited by 772
Self-citationPrevention of muscular dystrophy in mice by CRISPR/Cas9–mediated editing of germline DNA
Long, C., McAnally, J. R., Shelton, J. M., Mireault, A. A., Bassel-Duby, R., & Olson, E. N. (2014) · Science · doi:10.1126/science.1254445 · Cited by 720
Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
Goemans, N. M., Tulinius, M., van den Akker, J. T., Burm, B. E., Ekhart, P. F., Heuvelmans, N., Holling, T., Janson, A. A., Platenburg, G. J., Sipkens, J. A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011367 · Cited by 678
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655
Very mild muscular dystrophy associated with the deletion of 46% of dystrophin
England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623
Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart
Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., Chen, C., Li, J., & Xiao, X. (2005) · Nature Biotechnology · doi:10.1038/nbt1073 · Cited by 608
Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy
Harper, S. Q., Hauser, M. A., DelloRusso, C., Duan, D., Crawford, R. W., Phelps, S. F., Harper, H. A., Robinson, A. S., Engelhardt, J. F., Brooks, S. V., et al. (2002) · Nature Medicine · doi:10.1038/nm0302-253 · Cited by 579
Self-citationAartsma-Rus, A., Fokkema, I., Verschuuren, J., Ginjaar, I., van Deutekom, J., van Ommen, G.-J., & den Dunnen, J. T. (2009) · Human Mutation · doi:10.1002/humu.20918 · Cited by 575
Wang, B., Li, J., & Xiao, X. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.240335297 · Cited by 508
A Rapid and General Assay for Monitoring Endogenous Gene Modification
Guschin, D. Y., Waite, A. J., Katibah, G. E., Miller, J. C., Holmes, M. C., & Rebar, E. J. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-753-2_15 · Cited by 499
Li, H. L., Fujimoto, N., Sasakawa, N., Shirai, S., Ohkame, T., Sakuma, T., Tanaka, M., Amano, N., Watanabe, A., Sakurai, H., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.10.013 · Cited by 471
Ousterout, D. G., Kabadi, A. M., Thakore, P. I., Majoros, W. H., Reddy, T. E., & Gersbach, C. A. (2015) · Nature Communications · doi:10.1038/ncomms7244 · Cited by 470
Self-citationLai, Y., Thomas, G. D., Yue, Y., Yang, H. T., Li, D., Long, C., Judge, L., Bostick, B., Chamberlain, J. S., Terjung, R. L., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36612 · Cited by 389
Self-citationAntisense-induced exon skipping and synthesis of dystrophin in the mdx mouse
Mann, C. J., Honeyman, K., Cheng, A. J., Ly, T., Lloyd, F., Fletcher, S., Morgan, J. E., Partridge, T. A., & Wilton, S. D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.42 · Cited by 388
Wang, D., Mou, H., Li, S., Li, Y., Hough, S., Tran, K., Li, J., Yin, H., Anderson, D. G., Sontheimer, E. J., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.087 · Cited by 345
Goyenvalle, A., Griffith, G., Babbs, A., Andaloussi, S. E., Ezzat, K., Avril, A., Dugovic, B., Chaussenot, R., Ferry, A., Voit, T., et al. (2015) · Nature Medicine · doi:10.1038/nm.3765 · Cited by 327
Sarcolemma-localized nNOS is required to maintain activity after mild exercise
Kobayashi, Y. M., Rader, E. P., Crawford, R. W., Iyengar, N. K., Thedens, D. R., Faulkner, J. A., Parikh, S. V., Weiss, R. M., Chamberlain, J. S., Moore, S. A., et al. (2008) · Nature · doi:10.1038/nature07414 · Cited by 286
CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice
Xu, L., Park, K. H., Zhao, L., Xu, J., El Refaey, M., Gao, Y., Zhu, H., Ma, J., & Han, R. (2016) · Molecular Therapy · doi:10.1038/mt.2015.192 · Cited by 244
Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches
Fairclough, R. J., Wood, M. J., & Davies, K. E. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3460 · Cited by 229
Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors
Lai, Y., Yue, Y., Liu, M., Ghosh, A., Engelhardt, J. F., Chamberlain, J. S., & Duan, D. (2005) · Nature Biotechnology · doi:10.1038/nbt1153 · Cited by 224
Self-citationOusterout, D. G., Perez-Pinera, P., Thakore, P. I., Kabadi, A. M., Brown, M. T., Qin, X., Fedrigo, O., Mouly, V., Tremblay, J. P., & Gersbach, C. A. (2013) · Molecular Therapy · doi:10.1038/mt.2013.111 · Cited by 181
Self-citationDystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human
Neri, M., Torelli, S., Brown, S., Ugo, I., Sabatelli, P., Merlini, L., Spitali, P., Rimessi, P., Gualandi, F., Sewry, C., et al. (2007) · Neuromuscular Disorders · doi:10.1016/j.nmd.2007.07.005 · Cited by 173
Microdystrophin Ameliorates Muscular Dystrophy in the Canine Model of Duchenne Muscular Dystrophy
Shin, J., Pan, X., Hakim, C. H., Yang, H. T., Yue, Y., Zhang, K., Terjung, R. L., & Duan, D. (2013) · Molecular Therapy · doi:10.1038/mt.2012.283 · Cited by 146
Self-citationOusterout, D. G., Kabadi, A. M., Thakore, P. I., Pérez‐Piñera, P., Brown, M. T., Majoros, W. H., Reddy, T. E., & Gersbach, C. A. (2014) · Molecular Therapy · doi:10.1038/mt.2014.234 · Cited by 129
Self-citationvan Putten, M., Hulsker, M., Young, C. S., Nadarajah, V. D., Heemskerk, H., van der Weerd, L., Hoen, P. A. C. ’., van Ommen, G. B., & Aartsma-Rus, A. M. (2013) · The FASEB Journal · doi:10.1096/fj.12-224170 · Cited by 115
Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin
Li, D., Bareja, A., Judge, L. M., Yue, Y., Lai, Y., Fairclough, R. J., Davies, K. E., Chamberlain, J. S., & Duan, D. (2010) · Journal of Cell Science · doi:10.1242/jcs.064808 · Cited by 110
Self-citationMeganucleases can restore the reading frame of a mutated dystrophin
Chapdelaine, P., Pichavant, C., Rousseau, J., Pâques, F., & Tremblay, J. P. (2010) · Gene Therapy · doi:10.1038/gt.2010.26 · Cited by 95
Hakim, C. H., Wasala, N. B., & Duan, D. (2013) · Journal of Visualized Experiments · doi:10.3791/50183 · Cited by 92
Self-citationGene Correction of a Duchenne Muscular Dystrophy Mutation by Meganuclease-Enhanced Exon Knock-In
Popplewell, L. J., Koo, T., Leclerc, X., Duclert, A., Mamchaoui, K., Gouble, A., Mouly, V., Voït, T., Pâques, F., Cédrone, F., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.081 · Cited by 73
Li, D., Yue, Y., & Duan, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015286 · Cited by 62
Self-citationGene Therapy for Muscular Dystrophy: Moving the Field Forward
Al-Zaidy, S. A., Rodino‐Klapac, L. R., & Mendell, J. R. (2014) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2014.08.002 · Cited by 45
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The next generation of CRISPR–Cas technologies and applications
Pickar-Oliver, A., & Gersbach, C. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0131-5 · Cited by 1,459
Self-citationDunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
Delivering CRISPR: a review of the challenges and approaches
Lino, C. A., Harper, J. C., Carney, J. P., & Timlin, J. A. (2018) · Drug Delivery · doi:10.1080/10717544.2018.1474964 · Cited by 1,185
Metadata
- Authors
- Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., Asokan, A., Zhang, F., Duan, D., & Gersbach, C. A.
- Affiliations
- Duke University (US)
- University of Missouri (US)
- University of North Carolina at Chapel Hill (US)
- Broad Institute (US)
- Corresponding author
- Gersbach, Charles A.
- ORCID
- Venue
- Science
- Published
- 2016-01-22
- Volume
- 351
- Issue
- 6271
- Pages
- 403-407
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4883596
- OpenAlex
- W2208696160
- Cited by
- 1,144
- References
- 48
- Citations by year
- 2026: 37 · 2025: 52 · 2024: 52 · 2023: 67 · 2022: 92 · 2021: 101 · 2020: 124 · 2019: 139 · 2018: 165 · 2017: 169 · 2016: 143
- FWCI
- 68.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Muscular Dystrophy Association (MDA277360)
- Duke-Coulter Translational Partnership Grant
- March of Dimes Foundation
- NSF
- Keck
- Damon Runyon
- Searle Scholars
- Merkin Family
- Vallee
- Simons
- Paul G. Allen
- New York Stem Cell Foundation
- Bob Metcalfe
- NIH (DP2-OD008586, DP1-MH100706, R01DK097768, R01HL089221, P01HL112761, R01NS90634)
- Hope for Javier Foundation
- Hartwell Foundation
- American Heart Association
- National Institute of General Medical Sciences (T32GM007753)
- Paul and Daisy Soros Fellowship
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- Duchenne muscular dystrophy, CRISPR/Cas9 genome editing, dystrophin gene, adeno-associated virus vectors, mdx mice, in vivo gene therapy, muscle function, myocardium, muscle force, dystrophin expression
- MeSH terms
- Dependovirus, Animals, Disease Models, Animal, Exons, Male, Genetic Therapy, Dystrophin, Sequence Deletion, Mice, Inbred mdx, Muscle, Skeletal, Muscular Dystrophy, Duchenne, Mice, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.